4.2100 0.00 (0.00%)
After hours: 4:15PM EDT
Shares of Organogenesis Holdings (NASDAQ: ORGO) are up by 15.5% as of 1:15 p.m. EDT on Thursday after rising by as much as 28% earlier today. For the third quarter ending on Sept. 30, Organogenesis Holdings expects its revenue to come in between $99 million and $100 million. Organogenesis Holdings' top line is also set to exceed the $71.96 million average estimate analysts were expecting.
Simply stated, we believe our second-quarter revenue performance is a direct result of the organization's resilience in the face of these unprecedented challenges and the dedication of our employees to our customers and patients. One, the investment that we've made to expand our sales force over the recent years, strong execution of our commercial strategy and the benefits of our comprehensive portfolio and solutions we offer in the Advanced Wound Care and Surgical & Sports Medicine markets.
Organogenesis (ORGO) delivered earnings and revenue surprises of 58.33% and 0.97%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?